Aim: MCP-1 (monocyte chemo attractant protein-1) plays an important role on atherosclerotic lessions. We studied the association of MCP-1 with left ventricular hypertrophy (LVH) and coronary artery disease (CAD) as manifestations of cardiovascular disease in patients on the end stage of renal disease. Methods: We included 76 patients on on-line hemodiafiltration. The sodium removal and the ratio of LDL/HDL were calculated. Serum MCP-1 concentrations were measured using enzyme linked immunoabsorbed assay (ELISA).We performed a logistic-regression analysis to investigate the impact of MCP-1 on LVH and CAD after adjustment for the traditional and specific cardiovascular risk factors for dialysis patients.
Results: We found a positive correlation of MCP-1 with LDL/HDL ratio, but inverse association with sodium removal (r=0.315, p=0.04 and r=-0.288, p=0.01 respectively).The built logistic-regression analysis did not show significant impact of MCP-1 on CAD, but it was found as a significant independent predictor of LVH (B=0.004, p=0.04, OR=1.004, 1.000-1.008).
Conclusion: We observed a significant impact of MCP-1 serum concentrations on the LVH in patients on the end stage of renal disease, due may to its relationship with sodium retention and fluid overload, but we did not find a significant association with CAD. Pharmaceutical inhibition of this chemokine may be usefull for these patients, but more studies need to support such a conclusion.